We have located links that may give you full text access.
AJCC 8th Edition oral cavity squamous cell carcinoma staging - Is it an improvement on the AJCC 7th Edition?
Oral Oncology 2018 July
OBJECTIVES: To explore the prognostic and discriminatory ability of the AJCC 8th Edition Oral Cavity cancer staging in a non-North American population, and compare it to the previously used AJCC 7th Edition.
MATERIALS AND METHODS: Retrospective chart review was performed at a tertiary referral Otolaryngology, Head Neck and Skull Base Department in Australia, from June 2002 to June 2017. Oral cavity squamous cell carcinoma cases were staged according to AJCC 8th Edition, which was compared to AJCC 7th Edition staging, for disease-free survival (DFS) and overall survival (OS). DFS and OS were analysed using Kaplan-Meier curves.
RESULTS: There were 118 patients treated for OSCC, with an average age of 61 years, 63% were male. Overall survival grouped by stage demonstrated statistically significant discrimination between cancer stages using both the AJCC 7th and AJCC 8th Editions. AJCC 7th Edition did not discriminate between stages for DFS. Conversely, AJCC 8th Edition did statistically significantly discriminate for DFS (p = 0.0002). The DFS for both Stage 4a and 4b was significantly worse than cases in Stage 1. AJCC 8th Edition T stage was statistically significantly related to DFS (p = 0.0199), while the AJCC 7th Edition T stage was not.
CONCLUSION: The AJCC Cancer Staging Manual 8th Edition includes both the depth of primary tumour invasion and extracapsular extension of lymph node metastases. The AJCC 8th Edition OSCC staging system showed improved disease-free survival discrimination between overall stages and between T categories, while AJCC 7th Edition did not.
MATERIALS AND METHODS: Retrospective chart review was performed at a tertiary referral Otolaryngology, Head Neck and Skull Base Department in Australia, from June 2002 to June 2017. Oral cavity squamous cell carcinoma cases were staged according to AJCC 8th Edition, which was compared to AJCC 7th Edition staging, for disease-free survival (DFS) and overall survival (OS). DFS and OS were analysed using Kaplan-Meier curves.
RESULTS: There were 118 patients treated for OSCC, with an average age of 61 years, 63% were male. Overall survival grouped by stage demonstrated statistically significant discrimination between cancer stages using both the AJCC 7th and AJCC 8th Editions. AJCC 7th Edition did not discriminate between stages for DFS. Conversely, AJCC 8th Edition did statistically significantly discriminate for DFS (p = 0.0002). The DFS for both Stage 4a and 4b was significantly worse than cases in Stage 1. AJCC 8th Edition T stage was statistically significantly related to DFS (p = 0.0199), while the AJCC 7th Edition T stage was not.
CONCLUSION: The AJCC Cancer Staging Manual 8th Edition includes both the depth of primary tumour invasion and extracapsular extension of lymph node metastases. The AJCC 8th Edition OSCC staging system showed improved disease-free survival discrimination between overall stages and between T categories, while AJCC 7th Edition did not.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app